Review



alk1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech alk1
    FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, <t>ALK1,</t> and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.
    Alk1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alk1/product/Proteintech
    Average 93 stars, based on 8 article reviews
    alk1 - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Sodium Hyaluronate-PDGF Repairs Cartilage and Subchondral Bone Microenvironment via HIF-1α-VEGF-Notch and SDF-1-CXCR4 Inhibition in Osteoarthritis."

    Article Title: Sodium Hyaluronate-PDGF Repairs Cartilage and Subchondral Bone Microenvironment via HIF-1α-VEGF-Notch and SDF-1-CXCR4 Inhibition in Osteoarthritis.

    Journal: Journal of cellular and molecular medicine

    doi: 10.1111/jcmm.70515

    FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, ALK1, and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.
    Figure Legend Snippet: FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, ALK1, and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.

    Techniques Used: Expressing, In Vivo



    Similar Products

    goat anti alk1  (R&D Systems)
    93
    R&D Systems goat anti alk1
    (A) Wholemount immunostaining of cerebral cortex slices for VE-cadherin and <t>ALK1</t> from P31 control and Alk1 iΔAEC mice (25µg tamoxifen on P2). (B) Wholemount immunostaining for CD31 and ALK1 in cerebral cortex slices of P10 control and Alk1 iΔAEC mice expressing Efnb2 H2B-GFP (50µg tamoxifen on P2). A and V label arteries and veins, respectively. Dashed outlines in ALK1 images indicate artery position.
    Goat Anti Alk1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti alk1/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    goat anti alk1 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    alk1  (Proteintech)
    93
    Proteintech alk1
    FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, <t>ALK1,</t> and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.
    Alk1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alk1/product/Proteintech
    Average 93 stars, based on 1 article reviews
    alk1 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    mouse anti-alk1  (R&D Systems Hematology)
    90
    R&D Systems Hematology mouse anti-alk1
    FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, <t>ALK1,</t> and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.
    Mouse Anti Alk1, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-alk1/product/R&D Systems Hematology
    Average 90 stars, based on 1 article reviews
    mouse anti-alk1 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    human anti-alk1  (R&D Systems Hematology)
    90
    R&D Systems Hematology human anti-alk1
    FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, <t>ALK1,</t> and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.
    Human Anti Alk1, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human anti-alk1/product/R&D Systems Hematology
    Average 90 stars, based on 1 article reviews
    human anti-alk1 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    anti alk1 human  (Proteintech)
    93
    Proteintech anti alk1 human
    FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, <t>ALK1,</t> and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.
    Anti Alk1 Human, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti alk1 human/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti alk1 human - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    rabbit anti-alk1/acvrl1  (WuXi AppTec)
    90
    WuXi AppTec rabbit anti-alk1/acvrl1
    A. Western blot showing β1-integrin, TGFβ1, <t>ALK1</t> levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. B. Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9. N=3, ≥ 20 cells per condition per rep. C. Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFβ1. N=3, ≥ 20 cells per condition per rep. D. Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). N=3, ≥ 20 cells per condition per rep. E. Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. N=3, at least 20 cells per condition per rep. F. Total cell lysates of B16F1 cells were seeded on PDL +/− THSD7A and treated with or without TGF-β1 and inhibitor. Cell lysates were probed for phospho-Smad and total Smad levels. Representative of 3 blots. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.
    Rabbit Anti Alk1/Acvrl1, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti-alk1/acvrl1/product/WuXi AppTec
    Average 90 stars, based on 1 article reviews
    rabbit anti-alk1/acvrl1 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    alk1  (Danaher Inc)
    86
    Danaher Inc alk1
    A. Western blot showing β1-integrin, TGFβ1, <t>ALK1</t> levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. B. Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9. N=3, ≥ 20 cells per condition per rep. C. Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFβ1. N=3, ≥ 20 cells per condition per rep. D. Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). N=3, ≥ 20 cells per condition per rep. E. Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. N=3, at least 20 cells per condition per rep. F. Total cell lysates of B16F1 cells were seeded on PDL +/− THSD7A and treated with or without TGF-β1 and inhibitor. Cell lysates were probed for phospho-Smad and total Smad levels. Representative of 3 blots. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.
    Alk1, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alk1/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    alk1 - by Bioz Stars, 2026-03
    86/100 stars
    		  Buy from Supplier
    monoclonal anti-alk1 #mab370  (Novus Biologicals)
    90
    Novus Biologicals monoclonal anti-alk1 #mab370
    A. Western blot showing β1-integrin, TGFβ1, <t>ALK1</t> levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. B. Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9. N=3, ≥ 20 cells per condition per rep. C. Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFβ1. N=3, ≥ 20 cells per condition per rep. D. Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). N=3, ≥ 20 cells per condition per rep. E. Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. N=3, at least 20 cells per condition per rep. F. Total cell lysates of B16F1 cells were seeded on PDL +/− THSD7A and treated with or without TGF-β1 and inhibitor. Cell lysates were probed for phospho-Smad and total Smad levels. Representative of 3 blots. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.
    Monoclonal Anti Alk1 #Mab370, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal anti-alk1 #mab370/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    monoclonal anti-alk1 #mab370 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    anti alk1  (Danaher Inc)
    86
    Danaher Inc anti alk1
    A. Western blot showing β1-integrin, TGFβ1, <t>ALK1</t> levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. B. Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9. N=3, ≥ 20 cells per condition per rep. C. Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFβ1. N=3, ≥ 20 cells per condition per rep. D. Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). N=3, ≥ 20 cells per condition per rep. E. Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. N=3, at least 20 cells per condition per rep. F. Total cell lysates of B16F1 cells were seeded on PDL +/− THSD7A and treated with or without TGF-β1 and inhibitor. Cell lysates were probed for phospho-Smad and total Smad levels. Representative of 3 blots. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.
    Anti Alk1, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti alk1/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    anti alk1 - by Bioz Stars, 2026-03
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Wholemount immunostaining of cerebral cortex slices for VE-cadherin and ALK1 from P31 control and Alk1 iΔAEC mice (25µg tamoxifen on P2). (B) Wholemount immunostaining for CD31 and ALK1 in cerebral cortex slices of P10 control and Alk1 iΔAEC mice expressing Efnb2 H2B-GFP (50µg tamoxifen on P2). A and V label arteries and veins, respectively. Dashed outlines in ALK1 images indicate artery position.

    Journal: bioRxiv

    Article Title: Arterial endothelial deletion of Alk1 causes epistaxis and cerebral microhemorrhage with aberrant arteries and defective smooth muscle coverage

    doi: 10.1101/2024.11.25.622742

    Figure Lengend Snippet: (A) Wholemount immunostaining of cerebral cortex slices for VE-cadherin and ALK1 from P31 control and Alk1 iΔAEC mice (25µg tamoxifen on P2). (B) Wholemount immunostaining for CD31 and ALK1 in cerebral cortex slices of P10 control and Alk1 iΔAEC mice expressing Efnb2 H2B-GFP (50µg tamoxifen on P2). A and V label arteries and veins, respectively. Dashed outlines in ALK1 images indicate artery position.

    Article Snippet: Antibodies and fluorescent probes used in this study include: (1) rat anti-CD31 (BD Pharmingen 555370; 1:500 dilution), (2) mouse anti-α-smooth muscle actin-Cy3-conjugated antibody (Sigma, C6198/F3777; 1:2000 dilution), (3) mouse anti-α-smooth muscle actin-Alexa Fluor 488-conjugated antibody (eBioscience,53-9760-82; 1:2000 dilution), (4) rat anti-VE-cadherin (BD Pharmingen, 555289, 1:200 dilution), (5) goat anti-ALK1 (R&D Systems, 1:200 dilution), (6) donkey anti-rat Alexa Fluor 488 (Invitrogen, A-11006, 1:1000 dilution), (7) donkey anti-rat Alexa Fluor 555 (Invitrogen, A21434, 1:1000 dilution), and (8) donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch Labs, 712-605-150, 1:500 dilution).

    Techniques: Immunostaining, Control, Expressing

    (A) Photograph of P33 Alk1 iΔAEC mouse with blood on nose (arrowhead). (B) Photograph of blood present (arrowhead) in cage housing P81 Alk1 iΔAEC mice. (C) Gross pathological images demonstrating multi-focal hemorrhages (arrowheads) present in Alk1 iΔAEC mice brains but absent in control at P7. All mice administered 25µg tamoxifen on P2.

    Journal: bioRxiv

    Article Title: Arterial endothelial deletion of Alk1 causes epistaxis and cerebral microhemorrhage with aberrant arteries and defective smooth muscle coverage

    doi: 10.1101/2024.11.25.622742

    Figure Lengend Snippet: (A) Photograph of P33 Alk1 iΔAEC mouse with blood on nose (arrowhead). (B) Photograph of blood present (arrowhead) in cage housing P81 Alk1 iΔAEC mice. (C) Gross pathological images demonstrating multi-focal hemorrhages (arrowheads) present in Alk1 iΔAEC mice brains but absent in control at P7. All mice administered 25µg tamoxifen on P2.

    Article Snippet: Antibodies and fluorescent probes used in this study include: (1) rat anti-CD31 (BD Pharmingen 555370; 1:500 dilution), (2) mouse anti-α-smooth muscle actin-Cy3-conjugated antibody (Sigma, C6198/F3777; 1:2000 dilution), (3) mouse anti-α-smooth muscle actin-Alexa Fluor 488-conjugated antibody (eBioscience,53-9760-82; 1:2000 dilution), (4) rat anti-VE-cadherin (BD Pharmingen, 555289, 1:200 dilution), (5) goat anti-ALK1 (R&D Systems, 1:200 dilution), (6) donkey anti-rat Alexa Fluor 488 (Invitrogen, A-11006, 1:1000 dilution), (7) donkey anti-rat Alexa Fluor 555 (Invitrogen, A21434, 1:1000 dilution), and (8) donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch Labs, 712-605-150, 1:500 dilution).

    Techniques: Control

    Kaplan-Meier analysis showed that time to moribundity in Alk1 iΔAEC mice administered 100µg tamoxifen on P2 and P3 (red triangles) was significantly faster (median 23 days) than control (black circles) and Alk1 iΔAEC mice administered 25µg tamoxifen on P2 (N = 45-80 mice per condition).

    Journal: bioRxiv

    Article Title: Arterial endothelial deletion of Alk1 causes epistaxis and cerebral microhemorrhage with aberrant arteries and defective smooth muscle coverage

    doi: 10.1101/2024.11.25.622742

    Figure Lengend Snippet: Kaplan-Meier analysis showed that time to moribundity in Alk1 iΔAEC mice administered 100µg tamoxifen on P2 and P3 (red triangles) was significantly faster (median 23 days) than control (black circles) and Alk1 iΔAEC mice administered 25µg tamoxifen on P2 (N = 45-80 mice per condition).

    Article Snippet: Antibodies and fluorescent probes used in this study include: (1) rat anti-CD31 (BD Pharmingen 555370; 1:500 dilution), (2) mouse anti-α-smooth muscle actin-Cy3-conjugated antibody (Sigma, C6198/F3777; 1:2000 dilution), (3) mouse anti-α-smooth muscle actin-Alexa Fluor 488-conjugated antibody (eBioscience,53-9760-82; 1:2000 dilution), (4) rat anti-VE-cadherin (BD Pharmingen, 555289, 1:200 dilution), (5) goat anti-ALK1 (R&D Systems, 1:200 dilution), (6) donkey anti-rat Alexa Fluor 488 (Invitrogen, A-11006, 1:1000 dilution), (7) donkey anti-rat Alexa Fluor 555 (Invitrogen, A21434, 1:1000 dilution), and (8) donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch Labs, 712-605-150, 1:500 dilution).

    Techniques: Control

    (A) MICROFIL casting of nasal cavity and cranial exterior of control (P16) and Alk1 iΔAEC (P19) mice revealed enlarged and tortuous vessels in Alk1 iΔAEC mouse (100µg tamoxifen on P2 & P3). Black and white arrowheads indicate the facial artery/vein pair and a tangle of blood vessels in the distal nasal vestibule, respectively. Mouse schematic created in BioRender.com. (B) Wholemount immunostaining for CD31 and Rosa26 Ai75 Cre reporter signal in nasal mucosa of P21 control ( Bmx-Cre ERT2 ; Alk1 fx/+ ) and Alk1 iΔAEC mice (25µg tamoxifen on P2). Blue dashed line indicates the most dorsal crease of the nasal cavity. Caudal (C), rostral (R), dorsal (D), and ventral (V) directions are indicated.

    Journal: bioRxiv

    Article Title: Arterial endothelial deletion of Alk1 causes epistaxis and cerebral microhemorrhage with aberrant arteries and defective smooth muscle coverage

    doi: 10.1101/2024.11.25.622742

    Figure Lengend Snippet: (A) MICROFIL casting of nasal cavity and cranial exterior of control (P16) and Alk1 iΔAEC (P19) mice revealed enlarged and tortuous vessels in Alk1 iΔAEC mouse (100µg tamoxifen on P2 & P3). Black and white arrowheads indicate the facial artery/vein pair and a tangle of blood vessels in the distal nasal vestibule, respectively. Mouse schematic created in BioRender.com. (B) Wholemount immunostaining for CD31 and Rosa26 Ai75 Cre reporter signal in nasal mucosa of P21 control ( Bmx-Cre ERT2 ; Alk1 fx/+ ) and Alk1 iΔAEC mice (25µg tamoxifen on P2). Blue dashed line indicates the most dorsal crease of the nasal cavity. Caudal (C), rostral (R), dorsal (D), and ventral (V) directions are indicated.

    Article Snippet: Antibodies and fluorescent probes used in this study include: (1) rat anti-CD31 (BD Pharmingen 555370; 1:500 dilution), (2) mouse anti-α-smooth muscle actin-Cy3-conjugated antibody (Sigma, C6198/F3777; 1:2000 dilution), (3) mouse anti-α-smooth muscle actin-Alexa Fluor 488-conjugated antibody (eBioscience,53-9760-82; 1:2000 dilution), (4) rat anti-VE-cadherin (BD Pharmingen, 555289, 1:200 dilution), (5) goat anti-ALK1 (R&D Systems, 1:200 dilution), (6) donkey anti-rat Alexa Fluor 488 (Invitrogen, A-11006, 1:1000 dilution), (7) donkey anti-rat Alexa Fluor 555 (Invitrogen, A21434, 1:1000 dilution), and (8) donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch Labs, 712-605-150, 1:500 dilution).

    Techniques: Control, Immunostaining

    (A) MICROFIL casting of the brain demonstrating tortuous vessels in control and Alk1 iΔAEC mice at P24 (100µg tamoxifen on P2 & P3). (B) Wholemount immunostaining for CD31 in cerebral cortex slices of P31 control and Alk1 iΔAEC mice (75µg tamoxifen on P2).

    Journal: bioRxiv

    Article Title: Arterial endothelial deletion of Alk1 causes epistaxis and cerebral microhemorrhage with aberrant arteries and defective smooth muscle coverage

    doi: 10.1101/2024.11.25.622742

    Figure Lengend Snippet: (A) MICROFIL casting of the brain demonstrating tortuous vessels in control and Alk1 iΔAEC mice at P24 (100µg tamoxifen on P2 & P3). (B) Wholemount immunostaining for CD31 in cerebral cortex slices of P31 control and Alk1 iΔAEC mice (75µg tamoxifen on P2).

    Article Snippet: Antibodies and fluorescent probes used in this study include: (1) rat anti-CD31 (BD Pharmingen 555370; 1:500 dilution), (2) mouse anti-α-smooth muscle actin-Cy3-conjugated antibody (Sigma, C6198/F3777; 1:2000 dilution), (3) mouse anti-α-smooth muscle actin-Alexa Fluor 488-conjugated antibody (eBioscience,53-9760-82; 1:2000 dilution), (4) rat anti-VE-cadherin (BD Pharmingen, 555289, 1:200 dilution), (5) goat anti-ALK1 (R&D Systems, 1:200 dilution), (6) donkey anti-rat Alexa Fluor 488 (Invitrogen, A-11006, 1:1000 dilution), (7) donkey anti-rat Alexa Fluor 555 (Invitrogen, A21434, 1:1000 dilution), and (8) donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch Labs, 712-605-150, 1:500 dilution).

    Techniques: Control, Immunostaining

    (A) Wholemount immunostaining for CD31 and α-smooth muscle actin (αSMA) in nasal mucosa of P103 control and Alk1 iΔAEC mice (100µg tamoxifen per g body weight on P13 & P14). (B) Photomicrographs of wholemount immunostaining for CD31 and αSMA in cerebral cortex slices of P31 control and Alk1 iΔAEC mice (75µg tamoxifen on P2). Red arrows indicate gaps in smooth muscle coverage. Blue arrow indicates regions of misaligned smooth muscle cells. Brain schematic created in BioRender.com.

    Journal: bioRxiv

    Article Title: Arterial endothelial deletion of Alk1 causes epistaxis and cerebral microhemorrhage with aberrant arteries and defective smooth muscle coverage

    doi: 10.1101/2024.11.25.622742

    Figure Lengend Snippet: (A) Wholemount immunostaining for CD31 and α-smooth muscle actin (αSMA) in nasal mucosa of P103 control and Alk1 iΔAEC mice (100µg tamoxifen per g body weight on P13 & P14). (B) Photomicrographs of wholemount immunostaining for CD31 and αSMA in cerebral cortex slices of P31 control and Alk1 iΔAEC mice (75µg tamoxifen on P2). Red arrows indicate gaps in smooth muscle coverage. Blue arrow indicates regions of misaligned smooth muscle cells. Brain schematic created in BioRender.com.

    Article Snippet: Antibodies and fluorescent probes used in this study include: (1) rat anti-CD31 (BD Pharmingen 555370; 1:500 dilution), (2) mouse anti-α-smooth muscle actin-Cy3-conjugated antibody (Sigma, C6198/F3777; 1:2000 dilution), (3) mouse anti-α-smooth muscle actin-Alexa Fluor 488-conjugated antibody (eBioscience,53-9760-82; 1:2000 dilution), (4) rat anti-VE-cadherin (BD Pharmingen, 555289, 1:200 dilution), (5) goat anti-ALK1 (R&D Systems, 1:200 dilution), (6) donkey anti-rat Alexa Fluor 488 (Invitrogen, A-11006, 1:1000 dilution), (7) donkey anti-rat Alexa Fluor 555 (Invitrogen, A21434, 1:1000 dilution), and (8) donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch Labs, 712-605-150, 1:500 dilution).

    Techniques: Immunostaining, Control

    (A) Wholemount immunostaining for CD31 and expression of Efnb2 H2B-GFP arterial endothelial reporter in nasal mucosa of P13 control and Alk1 iΔAEC mice (100µg tamoxifen per g body weight on P13 & P14). Red boxed indicates location of inset images. Black dashed line indicates position of artery. (B) Wholemount immunostaining for CD31 and expression of Rosa26 Ai75 Cre recombinase reporter and Efnb2 H2B-GFP arterial endothelial reporter in nasal mucosa of P13 control and Alk1 iΔAEC mice (25µg tamoxifen on P2). Red boxed indicates location of inset images. (C) Wholemount immunostaining for CD31 and expression of Efnb2 H2B-GFP arterial endothelial reporter in cerebral cortex slices of P13 control and Alk1 iΔAEC mice (25µg tamoxifen on P2). Mouse schematic created in BioRender.com. A and V label arteries and veins, respectively.

    Journal: bioRxiv

    Article Title: Arterial endothelial deletion of Alk1 causes epistaxis and cerebral microhemorrhage with aberrant arteries and defective smooth muscle coverage

    doi: 10.1101/2024.11.25.622742

    Figure Lengend Snippet: (A) Wholemount immunostaining for CD31 and expression of Efnb2 H2B-GFP arterial endothelial reporter in nasal mucosa of P13 control and Alk1 iΔAEC mice (100µg tamoxifen per g body weight on P13 & P14). Red boxed indicates location of inset images. Black dashed line indicates position of artery. (B) Wholemount immunostaining for CD31 and expression of Rosa26 Ai75 Cre recombinase reporter and Efnb2 H2B-GFP arterial endothelial reporter in nasal mucosa of P13 control and Alk1 iΔAEC mice (25µg tamoxifen on P2). Red boxed indicates location of inset images. (C) Wholemount immunostaining for CD31 and expression of Efnb2 H2B-GFP arterial endothelial reporter in cerebral cortex slices of P13 control and Alk1 iΔAEC mice (25µg tamoxifen on P2). Mouse schematic created in BioRender.com. A and V label arteries and veins, respectively.

    Article Snippet: Antibodies and fluorescent probes used in this study include: (1) rat anti-CD31 (BD Pharmingen 555370; 1:500 dilution), (2) mouse anti-α-smooth muscle actin-Cy3-conjugated antibody (Sigma, C6198/F3777; 1:2000 dilution), (3) mouse anti-α-smooth muscle actin-Alexa Fluor 488-conjugated antibody (eBioscience,53-9760-82; 1:2000 dilution), (4) rat anti-VE-cadherin (BD Pharmingen, 555289, 1:200 dilution), (5) goat anti-ALK1 (R&D Systems, 1:200 dilution), (6) donkey anti-rat Alexa Fluor 488 (Invitrogen, A-11006, 1:1000 dilution), (7) donkey anti-rat Alexa Fluor 555 (Invitrogen, A21434, 1:1000 dilution), and (8) donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch Labs, 712-605-150, 1:500 dilution).

    Techniques: Immunostaining, Expressing, Control

    (A) Schematic demonstrating location of pial vessel imaging during in vivo arterial tone assay. (B) Representative images of pial vasculature in live P13 control and Alk1 iΔAEC mice (100µg tamoxifen on P2 & P3) visualized through an open cranial window. aCSF, artificial cerebrospinal fluid. (C) Quantification of changes in acetylcholine-induced vasodilation between control and Alk1 iΔAEC mice (unpaired Student’s t-test). (D) Quantification of changes in arterial tone between control and Alk1 iΔAEC mice (Mann-Whitney U test).

    Journal: bioRxiv

    Article Title: Arterial endothelial deletion of Alk1 causes epistaxis and cerebral microhemorrhage with aberrant arteries and defective smooth muscle coverage

    doi: 10.1101/2024.11.25.622742

    Figure Lengend Snippet: (A) Schematic demonstrating location of pial vessel imaging during in vivo arterial tone assay. (B) Representative images of pial vasculature in live P13 control and Alk1 iΔAEC mice (100µg tamoxifen on P2 & P3) visualized through an open cranial window. aCSF, artificial cerebrospinal fluid. (C) Quantification of changes in acetylcholine-induced vasodilation between control and Alk1 iΔAEC mice (unpaired Student’s t-test). (D) Quantification of changes in arterial tone between control and Alk1 iΔAEC mice (Mann-Whitney U test).

    Article Snippet: Antibodies and fluorescent probes used in this study include: (1) rat anti-CD31 (BD Pharmingen 555370; 1:500 dilution), (2) mouse anti-α-smooth muscle actin-Cy3-conjugated antibody (Sigma, C6198/F3777; 1:2000 dilution), (3) mouse anti-α-smooth muscle actin-Alexa Fluor 488-conjugated antibody (eBioscience,53-9760-82; 1:2000 dilution), (4) rat anti-VE-cadherin (BD Pharmingen, 555289, 1:200 dilution), (5) goat anti-ALK1 (R&D Systems, 1:200 dilution), (6) donkey anti-rat Alexa Fluor 488 (Invitrogen, A-11006, 1:1000 dilution), (7) donkey anti-rat Alexa Fluor 555 (Invitrogen, A21434, 1:1000 dilution), and (8) donkey anti-rat Alexa Fluor 647 (Jackson Immunoresearch Labs, 712-605-150, 1:500 dilution).

    Techniques: Imaging, In Vivo, Control, MANN-WHITNEY

    FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, ALK1, and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.

    Journal: Journal of cellular and molecular medicine

    Article Title: Sodium Hyaluronate-PDGF Repairs Cartilage and Subchondral Bone Microenvironment via HIF-1α-VEGF-Notch and SDF-1-CXCR4 Inhibition in Osteoarthritis.

    doi: 10.1111/jcmm.70515

    Figure Lengend Snippet: FIGURE 6 | Effects of PDGF-BB and SH-PDGF on NFATc1, CXCR4, ALK1, and ALK5 expression in OA in vivo (5 rats in each group). (A and E) Effects of PDGF-BB and SH-PDGF on NFATc1 expression in subchondral bone determined by IF. (B and F) Effects of PDGF-BB and SH-PDGF on CXCR4 expression in cartilage, as shown by IF. (C and G) Effects of PDGF-BB and SH-PDGF on ALK1 expression in cartilage shown by IF. (D and H) Effects of PDGF-BB and SH-PDGF on ALK5 expression in cartilage, as shown by IF. ns, no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001.

    Article Snippet: The following primary antibodies were used: EMCN (1:500, rabbit, Proteintech), CD31 (1:500, rabbit, Proteintech), TRAP (1:200, rabbit, Proteintech), pimonidazole (1:50, mouse, Hypoxyprobe), HIF- 1α (1:500, rabbit, Proteintech), VEGF (1:300, rabbit, Proteintech), Notch1 (1:200, rabbit, Proteintech), Smad2 (1:500, rabbit, Proteintech), p- Smad2 (1:200, rabbit, Proteintech), Smad3 (1:500, rabbit, Proteintech), p- Smad3 (1:200, rabbit, Proteintech), NFATc1 (1:300, rabbit, Proteintech), SDF- 1 (1:300, rabbit, Proteintech), CXCR4 (1:200, rabbit, Proteintech), ALK1 (1:500, rabbit, Proteintech) and ALK5 (1:500, rabbit, Proteintech).

    Techniques: Expressing, In Vivo

    A. Western blot showing β1-integrin, TGFβ1, ALK1 levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. B. Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9. N=3, ≥ 20 cells per condition per rep. C. Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFβ1. N=3, ≥ 20 cells per condition per rep. D. Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). N=3, ≥ 20 cells per condition per rep. E. Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. N=3, at least 20 cells per condition per rep. F. Total cell lysates of B16F1 cells were seeded on PDL +/− THSD7A and treated with or without TGF-β1 and inhibitor. Cell lysates were probed for phospho-Smad and total Smad levels. Representative of 3 blots. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.

    Journal: bioRxiv

    Article Title: Secreted exosomes induce filopodia formation

    doi: 10.1101/2024.07.20.604139

    Figure Lengend Snippet: A. Western blot showing β1-integrin, TGFβ1, ALK1 levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. B. Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9. N=3, ≥ 20 cells per condition per rep. C. Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFβ1. N=3, ≥ 20 cells per condition per rep. D. Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). N=3, ≥ 20 cells per condition per rep. E. Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. N=3, at least 20 cells per condition per rep. F. Total cell lysates of B16F1 cells were seeded on PDL +/− THSD7A and treated with or without TGF-β1 and inhibitor. Cell lysates were probed for phospho-Smad and total Smad levels. Representative of 3 blots. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.

    Article Snippet: Antibodies (for cancer cells): rabbit anti-Endoglin (mouse specific) (#3290, Cell Signaling), rabbit anti-Endoglin (human specific) (#4335, Cell Signaling), rabbit anti-CD63 (ab68418, Abcam), rabbit anti-beta actin (#4970, Cell Signaling), rabbit anti-TSG101 (ab30871, Abcam), rabbit anti-flotillin-1 (#3253, Cell Signaling), rabbit anti-TGFbeta1 (ab92486, Abcam), mouse anti-HSP70 (sc-24, Santa Cruz), mouse anti-CD29 (beta1-integrin; #610467, BD Biosciences), rabbit anti-ALK1/ACVRL1 (Abcepta AP7807a), rabbit anti-Rab27a (#69295, Cell Signaling), rabbit anti-Hrs (M-79) (sc-30221, Santa Cruz), rabbit anti-GM130 (ThermoFisher MA5-35107), rabbit anti-THSD7A (HPA000923, Sigma), mouse anti-vinculin (Sigma-Aldrich V9131).

    Techniques: Western Blot, Control, Staining